Esempio: Heart Attack

Prove cliniche su Cancellazione del cromosoma 17p

Totale 22 risultati

NCT01744691

Completato

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Condizioni: Chronic Lymphocytic Leukemia With 17p Deletion; Small Lymphocytic Lymphoma With 17p Deletion
NCT02044822

Terminato

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Condizioni: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
NCT01889186

Completato

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Condizioni: Chronic Lymphocytic Leukemia; 17 p Deletion; Cancer of the Blood and Bone Marrow
NCT02337829

Attivo, non reclutamento

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Condizioni: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT02966756

Reclutamento

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Presence of 17p Deletion

Condizioni: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
NCT03406156

Attivo, non reclutamento

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Condizioni: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
NCT03190330

Reclutamento

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Condizioni: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell
NCT04124497

Reclutamento

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Condizioni: Multiple Myeloma; Deletion 17P Syndrome
NCT01465334

Terminato

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Condizioni: CLL; SLL
NCT02756611

Attivo, non reclutamento

A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor

Condizioni: Chronic Lymphocytic Leukemia
NCT01392079

Completato

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Condizioni: Chronic Lymphocytic Leukemia
NCT01745640

Completato

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Condizioni: Multiple Myeloma
NCT02015208

Completato

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Condizioni: Chronic Lymphocytic Leukemia
NCT01500733

Attivo, non reclutamento

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Condizioni: Leukemia; Leukemia, Lymphocytyc; CLL (Chronic Lymphocytic Leukemia); SLL (Small Lymphocytic Lymphoma)
NCT03700450

Reclutamento

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Condizioni: Multiple Myeloma
NCT02633059

Attivo, non reclutamento

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condizioni: Loss of Chromosome 17p; Recurrent Plasma Cell Myeloma
NCT03204188

Reclutamento

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Condizioni: Progressive Marrow Failure; Night Sweats for More Than 1 Month Without Evidence of Infection; Weight Loss of 10% or More Within the Previous 6 Months; Fevers Higher Than 100.5 Degress F or 38.0 Degrees C for 2 or More Weeks
NCT00506259

Completato

Treatment Strategies for Children With Smith-Magenis Syndrome

Condizioni: Developmental Delay Disorders; Chromosome Deletion; Mental Retardation; Sleep Disorders, Circadian Rhythm; Self Injurious Behavior
NCT03943342

Reclutamento

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Condizioni: Chronic Lymphocytic Leukemia; Loss of Chromosome 17p
NCT02980731

Attivo, non reclutamento

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

Condizioni: Chronic Lymphocytic Leukemia (CLL)
NCT00013559

Attivo, non reclutamento

Natural History Study of Smith-Magenis Syndrome

Condizioni: Smith-Magenis Syndrome (SMS)
NCT02758665

Attivo, non reclutamento

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Condizioni: Leukemia, Lymphocytic, Chronic